```html

Uradermatitis (Antibiotic‑Induced Skin Reaction)

Overview

Uradermatitis is a term used to describe a localized or generalized skin inflammation that occurs as a direct result of exposure to an antibiotic. The reaction can range from a mild, self‑limited rash to a severe, life‑threatening eruption such as Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Although the word “uradermatitis” is not universally used in the literature, clinicians frequently refer to it when the culprit is an antibiotic rather than an environmental irritant.

Antibiotic‑induced skin reactions are among the most common drug‑related adverse events. According to a 2022 review in the Journal of Allergy and Clinical Immunology, up to 10% of patients prescribed a systemic antibiotic develop some type of cutaneous manifestation, with β‑lactams (penicillins, cephalosporins) and sulfonamides accounting for more than 70% of cases.

The condition can affect anyone, but certain groups are at higher risk:

• Patients with a personal or family history of drug allergies.
• Individuals with underlying immune disorders (e.g., lupus, HIV).
• Older adults (≥65 years) because they often take multiple medications.
• People of Asian ancestry have a higher prevalence of HLA‑related antibiotic hypersensitivity (e.g., HLA‑B*58:01 with allopurinol; similar patterns are emerging for some fluoroquinolones).

Symptoms

The clinical picture depends on the immunologic pathway involved (type I immediate hypersensitivity vs. type IV delayed hypersensitivity) and on the specific antibiotic. Below is a comprehensive list of possible manifestations:

Early, mild reactions (usually within minutes to hours)

• Urticaria (hives): Raised, itchy wheals that blanch with pressure.
• Pruritus: Generalized itching without visible rash.
• Flushing or erythema: Diffuse redness, especially on the face and neck.

Delayed reactions (hours to days after exposure)

• Maculopapular rash: Flat red patches with small raised bumps, often starts on the trunk and spreads.
• Exanthematous drug eruption: The most common form of delayed dermatitis; may be itchy or burning.
• Fixed drug eruption: Round or oval red patches that recur at the same site with re‑exposure, sometimes leaving hyperpigmentation.
• Drug‑induced photosensitivity: Redness and swelling in sun‑exposed areas 24‑72 h after UV exposure.
• Vesicular or bullous lesions: Fluid‑filled blisters that can coalesce; seen with more severe type IV reactions.

Severe, life‑threatening reactions

• Stevens‑Johnson syndrome (SJS): Painful erythema, target lesions, mucosal involvement (eyes, mouth, genitalia), and skin detachment < 10% of body surface area.
• Toxic epidermal necrolysis (TEN): Similar to SJS but with >30% epidermal detachment; carries a mortality rate of 25‑40%.
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Rash, fever, facial edema, lymphadenopathy, eosinophilia, and possible organ involvement (liver, kidney, lung).
• Anaphylaxis: Rapid onset of urticaria, airway swelling, hypotension, and potentially fatal shock.

Causes and Risk Factors

Uradermatitis is fundamentally an immune‑mediated hypersensitivity reaction to a drug molecule or its metabolite. The key mechanisms include:

• IgE‑mediated (Type I) reactions: Immediate release of histamine and other mediators from mast cells; common with penicillins and sulfonamides.
• T‑cell‑mediated (Type IV) reactions: Drug‑specific T‑cells recognize the antibiotic as foreign, leading to cytokine release and skin inflammation; responsible for maculopapular eruptions, fixed drug eruptions, SJS/TEN, and DRESS.

Antibiotics most often implicated

1. Penicillins (amoxicillin, ampicillin, nafcillin)
2. Cephalosporins (cefazolin, cefuroxime, ceftriaxone)
3. Sulfonamides (trimethoprim‑sulfamethoxazole, sulfadiazine)
4. Fluoroquinolones (ciprofloxacin, levofloxacin)
5. Tetracyclines (doxycycline, minocycline)
6. Macrolides (azithromycin, clarithromycin) – less common but reported.

Additional risk factors

• Concomitant use of multiple high‑risk drugs (e.g., allopurinol + antibiotics).
• Renal or hepatic impairment leading to drug accumulation.
• Genetic predisposition (HLA‑B*15:02 for carbamazepine, similar alleles under investigation for antibiotics).
• Previous exposure to the same antibiotic class.

Diagnosis

Diagnosing uradermatitis relies on a combination of clinical history, physical examination, and, when necessary, laboratory or skin‑testing studies.

Step‑by‑step approach

1. Detailed medication history: Identify all antibiotics taken in the past 4 weeks, dose, route, and timing of symptom onset.
2. Physical examination: Document morphology, distribution, and extent of skin lesions; look for mucosal involvement or systemic signs (fever, lymphadenopathy).
3. Rule out mimickers: Viral exanthems, autoimmune diseases, and other drug eruptions.
4. Laboratory tests (if indicated):
   • Complete blood count – eosinophilia suggests DRESS.
   • Liver and renal panels – assess organ involvement.
   • C‑reactive protein or ESR – gauge inflammation.
5. Skin biopsy: Helpful for severe reactions (SJS/TEN, DRESS) to confirm epidermal necrosis or interface dermatitis.
6. Allergy testing:
   • Skin prick or intradermal testing for immediate IgE‑mediated reactions (mainly penicillins).
   • Patch testing for delayed hypersensitivity (commonly used for sulfonamides, β‑lactams).
   • In vitro tests (specific IgE, lymphocyte transformation test) are available in specialized centers.

Treatment Options

The cornerstone of management is prompt discontinuation of the offending antibiotic, followed by symptom‑directed therapy. Treatment varies with severity.

Mild to moderate reactions

• Antihistamines: Cetirizine 10 mg PO daily or diphenhydramine 25‑50 mg PO q6‑8 h for itching.
• Topical steroids: Hydrocortisone 1% cream BID or clobetasol propionate 0.05% once daily for localized plaques.
• Emollients/moisturizers: To restore barrier function and reduce xerosis.
• Systemic corticosteroids: Prednisone 0.5 mg/kg/day for 5‑7 days (short course) can be considered for extensive maculopapular eruptions, though evidence is mixed (see NIH guideline 2023).

Severe reactions (SJS, TEN, DRESS)

• Immediate hospitalization: Preferably in a burn unit or ICU with dermatology support.
• Supportive care: Fluid/electrolyte management, wound care, pain control, temperature regulation.
• Systemic immunomodulation:
  • IVIG 2 g/kg total dose divided over 3‑5 days – may halt disease progression (some RCTs show benefit).
  • Cyclosporine 3‑5 mg/kg/day – shown to reduce mortality in SJS/TEN (Cochrane review 2021).
  • Systemic steroids (e.g., methylprednisolone 1‑2 mg/kg/day) – controversial but used in many centers.
• Monitoring for organ dysfunction: Daily labs, ophthalmology exam for ocular involvement, and audiology if ototoxic antibiotics were used.

Adjunctive measures

• Antipyretics (acetaminophen) for fever.
• Broad‑spectrum antimicrobial prophylaxis only if secondary infection is suspected.
• Psychological support – severe drug reactions can be traumatic.

Living with Uradermatitis (antibiotic‑induced skin reaction)

Even after the acute episode resolves, many patients experience lingering issues such as pigment changes, pruritus, or anxiety about future drug exposure. Below are practical strategies for daily life.

Skin care routine

• Use fragrance‑free, hypoallergenic soaps and moisturizers twice daily.
• Apply a broad‑spectrum sunscreen (SPF 30 or higher) if photosensitivity was present.
• Avoid hot baths, harsh scrubs, and tight clothing that can irritate healing skin.

Medication management

• Maintain an up‑to‑date medication list with the specific antibiotic that triggered the reaction highlighted in red.
• Wear a medical alert bracelet indicating “antibiotic‑induced skin reaction – avoid β‑lactams & sulfonamides” (adjust per your specific culprit).
• Ask your pharmacist for “cross‑reactivity” information before any new prescription.

Follow‑up care

• Schedule a dermatology visit 2–4 weeks after resolution to assess scarring or post‑inflammatory hyperpigmentation.
• If you had DRESS, obtain baseline liver and kidney labs and repeat them at 3‑month intervals for 6 months.

Emotional wellbeing

• Join support groups (e.g., the American Contact Dermatitis Society forums) for shared experiences.
• Consider counseling if anxiety about taking medication recurs.

Prevention

Preventing another episode revolves around careful drug selection and patient education.

1. Allergy documentation: Ensure that the reaction is clearly recorded in the electronic health record and in your personal medication card.
2. Drug‑allergy testing: When a specific antibiotic is essential (e.g., for endocarditis), referral to an allergy specialist for skin testing or graded challenge can clarify safe alternatives.
3. Alternative antibiotics: Choose agents with a low cross‑reactivity profile. For penicillin allergy, cefazolin may be safe after negative skin testing; for sulfonamide reactions, consider trimethoprim‑sulfamethoxazole alternatives such as nitrofurantoin (if appropriate).
4. Educate healthcare providers: Inform every prescriber of the reaction; request “allergy check” prompts before antibiotic ordering.
5. Avoid self‑medication: Never use leftover antibiotics or over‑the‑counter formulations without professional guidance.

Complications

If uradermatitis is not recognized early or treatment is delayed, several complications may arise:

• Secondary bacterial infection: Impetiginized lesions can progress to cellulitis or sepsis.
• Scarring & pigmentary changes: Especially after SJS/TEN or bullous eruptions.
• Chronic pruritus: May require neuromodulators (e.g., gabapentin) for relief.
• Organ damage in DRESS: Hepatitis, interstitial nephritis, myocarditis, or pneumonitis can be irreversible.
• Vision loss: Ocular surface disease in SJS/TEN can lead to corneal scarring.
• Psychological sequelae: Post‑traumatic stress disorder (PTSD) has been reported after severe drug eruptions.

When to Seek Emergency Care

---

Sources: Mayo Clinic. Antibiotic allergy. 2023; CDC. Drug Allergy Surveillance. 2022; NIH. Management of Drug‑Induced Skin Reactions. 2023; WHO. Global Surveillance of Adverse Drug Reactions. 2021; Cleveland Clinic. Stevens‑Johnson Syndrome & TEN. 2024; Journal of Allergy and Clinical Immunology. Antibiotic‑Induced Cutaneous Reactions. 2022.

```